ServiceNow nears deal to acquire Veza for at least $1 bln - The Information
DUBLIN - Investment firm Citadel Group has disclosed a 1.67% stake in Avadel Pharmaceuticals plc, according to a regulatory filing published Wednesday.
The disclosure, made under Irish Takeover Panel rules, shows Citadel holds 1,631,117 shares representing a long position in the pharmaceutical company as of November 25, 2025. This includes 1,469,317 owned or controlled shares and 161,800 shares through stock-settled derivatives.
The filing also reveals Citadel maintains a short position of 1,103,185 shares, equivalent to 1.12% of Avadel’s outstanding stock. This position consists of 317,885 shares and 785,300 shares through stock-settled derivatives.
The disclosure documents numerous transactions conducted on November 25, with Citadel both purchasing and selling Avadel shares at prices ranging from $22.88 to $22.99 per share. The largest single purchase was for 22,562 shares at $22.92, while the largest sale involved 18,544 shares at $22.93.
Additionally, the filing details Citadel’s options positions in Avadel, including call and put options with various strike prices and expiration dates extending through January 2027.
The disclosure was made in compliance with Rule 8.3 of the Irish Takeover Panel Act, which requires public disclosure of dealings by persons with interests in relevant securities representing 1% or more during offer periods.
The information was provided in a Form 8.3 filing to the Regulatory Information Service.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.